<![CDATA[Anti-CD38 antibodies or antibody variants have been shown to provide therapeutics for the treatment of CD38-positive hematological malignancies.3, 4, 5, 6, 7 Introduction of the antibody against CD38 ]]>Anti-CD38 antibodies or antibody variants have been shown to provide therapeutics for the treatment of CD38-positive hematological malignancies.3, 4, 5, 6, 7 Introduction of the antibody against CD38 may, however, raise concerns of side effects such as an infusion reaction and pharmacological phenomena associated with the long half-life of the antibody. Although antibodies against CD38 have been administered to patients with myeloma or B-cell lymphoma, there has been no report of adverse effects.7, 8 Indeed, daratumumab, a novel therapeutic human CD38 antibody and humanized monoclonal CD38 antibody (SAR650984) (http://clinicaltrialsfeeds.org
/clinical-trials/show/NCT01084252), is currently in clinical trials. This therapeutic option could be ready for use anytime without manipulation of cells and may be useful for most myeloma patients.

301 Moved Permanently

favicon

(www.nature.com)

]]>https://dev.proinvestor.com/forum/topic/448379/anti-cd38-antibodies-or-antibody-variants-have-been-shown-to-provide-therapeutics-for-the-treatment-of-cd38-positive-hematological-malignancies3-4-5-6-7-introduction-of-the-antibody-against-cd38RSS for NodeSat, 20 Jun 2026 11:29:01 GMTFri, 02 Sep 2011 10:23:45 GMT60